Gonadorelin-Linked Trial NCT05827081 Updated: Phase 3 Recruiting

On 2026-08-21, a clinical trial record involving gonadorelin was updated. The trial, titled "Phase IIIb Study of Ribociclib + ET in Early Breast Cancer," is registered as NCT05827081. The study is listed as Phase 3. Its current status is recruiting, meaning the trial is actively enrolling participants as of this update. Gonadorelin remains an approved compound, and this record reflects its inclusion within the broader trial design without indicating any outcome or result at this time. No efficacy or safety findings have been reported in connection with this update. This brief reflects only the recruiting status and phase classification as listed in the trial registry entry. Readers interested in the study details, including eligibility and design, can consult the official registration record for further information. For additional context on gonadorelin as a compound, including its approved uses and background, readers can refer to the compound overview.